This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
MedTech Stocks to Watch for Earnings on Aug 3
by Zacks Equity Research
MedTech players are likely to have benefited from the consistent opening of economies and sales contributions from high testing demand. Let's see how CRL, CVS, BRKR and NUVA fare this time.
Waters (WAT) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of 4.56% and 1.24%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
PerkinElmer (PKI) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
PerkinElmer (PKI) delivered earnings and revenue surprises of 14.29% and 2.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Bruker (BRKR) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bruker (BRKR) Debuts NMR Test for Research on Long COVID Risks
by Zacks Equity Research
Bruker's (BRKR) PhenoRisk PACS RuO will facilitate clinical research to combat the risks of Long COVID syndrome.
Bruker (BRKR) International Growth Strong Amid Competition
by Zacks Equity Research
Bruker (BRKR) Nano Group's microelectronics and semiconductor metrology tools continue to perform well with ongoing strength in bookings and backlog.
Zacks Industry Outlook Highlights Mettler-Toledo International, Waters and Bruker
by Zacks Equity Research
Mettler-Toledo International, Waters and Bruker have been highlighted in this Industry Outlook article.
3 Stocks to Watch on Rising Demand for Scientific Instruments
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry participants like Mettler-Toledo (MTD), Waters (WAT) and Bruker (BRKR) are gaining from strong life science, pharmaceutical and academic end-market demand, as well as rising healthcare spending.
Bruker (BRKR) BSI & BEST Arms Drive Growth Amid Competition
by Zacks Equity Research
Bruker (BRKR) Nano Group's microelectronics and semiconductor metrology tools continue to perform well with ongoing strength in bookings and backlog.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bruker (BRKR) Debuts Module on Ultima Multiphoton Microscopes
by Zacks Equity Research
Bruker's (BRKR) NeuraLight 3D Ultra module offers revolutionary 3D holographic photostimulation to support neuroscience and optogenetics research applications.
Bruker (BRKR) to Advance 4D Proteomics With Latest Launch
by Zacks Equity Research
Bruker's (BRKR) timsTOF HT is enhanced for high-throughput, deep and unbiased plasma proteomics, and liquid biopsy biomarker research.
Why Is Bruker (BRKR) Up 6.3% Since Last Earnings Report?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bruker (BRKR) on strength across the BSI and BEST businesses.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Bruker (BRKR) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Revenue growth across the BSI and BEST businesses drove Bruker's (BRKR) first-quarter 2022 revenues.
Bruker (BRKR) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 19.51% and 3.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Waters (WAT) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of 20.69% and 9.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Bruker (BRKR) Unveils New Imaging Tools for Cancer Research
by Zacks Equity Research
Bruker's (BRKR) latest innovation for cancer research is likely to strengthen the company's opportunities in proteomics and spatial biology.
Bruker's (BRKR) Buyout to Expand Mass Spectrometry Prospects
by Zacks Equity Research
Bruker's (BRKR) acquisition of IonSense will reach the DART ionization technology to a wider customer base.
Bruker (BRKR) to Support Biopharma Industries With New Buyout
by Zacks Equity Research
Bruker's (BRKR) recent buyout strengthens the company as a key software and solutions provider for small molecule, biologics and new drug modalities pharma companies.
Here's Why You Should Add Bruker (BRKR) Stock to Your Kitty
by Zacks Equity Research
Bruker's (BRKR) Nano Group microelectronics and semiconductor metrology tools continue to perform well on ongoing strength in bookings and backlog.
Does Bruker (BRKR) Have the Potential to Rally 33% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 33.5% upside potential for Bruker (BRKR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.